Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
- Status
- COMPLETED
- Phase
- PHASE2
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
- Status
- COMPLETED
- Phase
- PHASE1
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
- Status
- COMPLETED
- Phase
- PHASE2
Palifermin After Haploidentical PBSCT
- Status
- WITHDRAWN
- Phase
- PHASE2
The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
- Status
- COMPLETED
- Phase
- PHASE2
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
- Status
- COMPLETED
- Phase
- PHASE2
Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)
- Status
- UNKNOWN
- Phase
- N/A
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
- Status
- COMPLETED
- Phase
- PHASE2
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant
- Status
- COMPLETED
- Phase
- N/A
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
- Status
- TERMINATED
- Phase
- PHASE2
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients
- Status
- COMPLETED
- Phase
- N/A
Cord Blood Expansion on Mesenchymal Stem Cells
- Status
- COMPLETED
- Phase
- PHASE1
SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE2
Treosulfan-based Conditioning for Transplantation in AML/MDS
- Status
- COMPLETED
- Phase
- PHASE2